Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes
Endocrinology and Metabolism Clinics of North America · 2026-09 · 55 (3) · 477-493
DOI: 10.1016/j.ecl.2026.04.007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2026-09. Verfasst von Stuti Fernandes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, Portland, OR, USA; Division…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glucagon-Like Peptide-1 Receptor Agonists, Mineralocorticoid Receptor Antagonists, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 67 Literaturangaben. Gefördert von: Breakthrough T1D, Bayer.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Sodium-glucose cotransporter inhibitors, glucagon-like peptide 1 receptor agonists and mineralocorticoid receptor blockers have revolutionized type 2 diabetes and by providing substantial cardiovascular and renal protection in this. This article summarizes the data for these newer agents in type 1 diabetes (T1D). Here we also emphasize the need for more long-term studies of these agents in T1D to assess their impact on cardiovascular risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, Portland, OR, USA; Division of Endocrinology, Veterans Health Administration, Portland, OR, USA.
- Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
- Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, Portland, OR, USA. Electronic address: busui@ohsu.edu.
Förderung
- Breakthrough T1D
- Bayer
Zitieren
APA
Fernandes, S., Hettinger, B., Ang, L., & Pop-Busui, R. (2026). Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 55(3), 477-493. https://doi.org/10.1016/j.ecl.2026.04.007
Vancouver
Fernandes S, Hettinger B, Ang L, Pop-Busui R. Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America. 2026;55(3):477-493. doi:10.1016/j.ecl.2026.04.007
BibTeX
@article{Fernandes2026,
author = {Fernandes, Stuti and Hettinger, Barbara and Ang, Lynn and Pop-Busui, Rodica},
title = {Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes},
journal = {Endocrinology and Metabolism Clinics of North America},
year = {2026},
volume = {55},
number = {3},
pages = {477--493},
doi = {10.1016/j.ecl.2026.04.007}
}
EUVIMED